These findings identified seven drivers of of prostate cancer, which may play an important role in clinical prognosis and management. This is of particular importance now, when over 80% of new cases of prostate cancer are diagnosed at a localized stage. Thus, the central challenge in patient care is to distinguish lethal cancer from slow-growing, indolent disease, which is not likely to cause symptoms in a man’s lifetime.
Groundbreaking work on prostate cancer genetics
National Cancer Institute and National Genome Project announced that the Cancer Genome Atlas (TCGA) Research Network produced groundbreaking results in research on genetic alterations in prostate cancer.
This study was published online in Cell on November 5, 2015 and led by Chris Sander, PhD, Memorial Sloan Kettering in New York.